Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

NCT01572181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancy

Interventions

DRUG: Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)

Sponsor

Nantes University Hospital